Clinical experience with sodium–glucose transport 2 (SGLT2) inhibitors in patients with systemic lupus erythematosus
This study suggests a potential benefit of SGLT2is in SLE patients. Further research is needed to confirm the nephro- and cardioprotective effects of SGLT2is in this population.
Authors
- Sydney Benchetrit
- Shaye Kivity (ORCID: https://orcid.org/0000-0002-8391-5446)
- Irina Kenis
- Keren Cohen‐Hagai (ORCID: https://orcid.org/0000-0003-1894-6956)
- Yael Pri-Paz Basson
- Oshrat E Tayer-Shifman (ORCID: https://orcid.org/0009-0008-3571-7243)
- Dorin Bar-Ziv
- Yair Levy (ORCID: https://orcid.org/0000-0003-2167-1260)
Institutions
- Tel Aviv University (IL)
- Meir Medical Center (IL)
- Clalit Health Services (IL)
Publication Details
- Journal
- International Urology and Nephrology
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1007/s11255-025-04815-5
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29